1
|
Olaizola-Rodrigo C, Palma-Florez S, Ranđelović T, Bayona C, Ashrafi M, Samitier J, Lagunas A, Mir M, Doblaré M, Ochoa I, Monge R, Oliván S. Tuneable hydrogel patterns in pillarless microfluidic devices. Lab Chip 2024; 24:2094-2106. [PMID: 38444329 DOI: 10.1039/d3lc01082a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/07/2024]
Abstract
Organ-on-chip (OOC) technology has recently emerged as a powerful tool to mimic physiological or pathophysiological conditions through cell culture in microfluidic devices. One of its main goals is bypassing animal testing and encouraging more personalized medicine. The recent incorporation of hydrogels as 3D scaffolds into microfluidic devices has changed biomedical research since they provide a biomimetic extracellular matrix to recreate tissue architectures. However, this technology presents some drawbacks such as the necessity for physical structures as pillars to confine these hydrogels, as well as the difficulty in reaching different shapes and patterns to create convoluted gradients or more realistic biological structures. In addition, pillars can also interfere with the fluid flow, altering the local shear forces and, therefore, modifying the mechanical environment in the OOC model. In this work, we present a methodology based on a plasma surface treatment that allows building cell culture chambers with abutment-free patterns capable of producing precise shear stress distributions. Therefore, pillarless devices with arbitrary geometries are needed to obtain more versatile, reliable, and biomimetic experimental models. Through computational simulation studies, these shear stress changes are demonstrated in different designed and fabricated geometries. To prove the versatility of this new technique, a blood-brain barrier model has been recreated, achieving an uninterrupted endothelial barrier that emulates part of the neurovascular network of the brain. Finally, we developed a new technology that could avoid the limitations mentioned above, allowing the development of biomimetic OOC models with complex and adaptable geometries, with cell-to-cell contact if required, and where fluid flow and shear stress conditions could be controlled.
Collapse
Affiliation(s)
- Claudia Olaizola-Rodrigo
- Tissue Microenvironment (TME), Lab. Aragón Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain.
- BEOnChip S.L., Zaragoza, Spain.
| | - Sujey Palma-Florez
- Nanobioengineering Group, Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Spain
- Department of Electronics and Biomedical Engineering, University of Barcelona, Martí i Franquès 1, 08028 Barcelona, Spain
| | - Teodora Ranđelović
- Tissue Microenvironment (TME), Lab. Aragón Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain.
- Institute for Health Research Aragón (IIS Aragón), Zaragoza, Spain
- CIBER-BBN, ISCIII, Spain
| | - Clara Bayona
- Tissue Microenvironment (TME), Lab. Aragón Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain.
- Institute for Health Research Aragón (IIS Aragón), Zaragoza, Spain
| | - Mehran Ashrafi
- Tissue Microenvironment (TME), Lab. Aragón Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain.
| | - Josep Samitier
- CIBER-BBN, ISCIII, Spain
- Nanobioengineering Group, Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Spain
- Department of Electronics and Biomedical Engineering, University of Barcelona, Martí i Franquès 1, 08028 Barcelona, Spain
| | - Anna Lagunas
- CIBER-BBN, ISCIII, Spain
- Nanobioengineering Group, Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Spain
| | - Mònica Mir
- CIBER-BBN, ISCIII, Spain
- Nanobioengineering Group, Institute for Bioengineering of Catalonia (IBEC), Barcelona Institute of Science and Technology (BIST), Spain
- Department of Electronics and Biomedical Engineering, University of Barcelona, Martí i Franquès 1, 08028 Barcelona, Spain
| | - Manuel Doblaré
- Tissue Microenvironment (TME), Lab. Aragón Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain.
- Institute for Health Research Aragón (IIS Aragón), Zaragoza, Spain
- CIBER-BBN, ISCIII, Spain
| | - Ignacio Ochoa
- Tissue Microenvironment (TME), Lab. Aragón Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain.
- Institute for Health Research Aragón (IIS Aragón), Zaragoza, Spain
- CIBER-BBN, ISCIII, Spain
| | | | - Sara Oliván
- Tissue Microenvironment (TME), Lab. Aragón Institute of Engineering Research (I3A), University of Zaragoza, Zaragoza, Spain.
- Institute for Health Research Aragón (IIS Aragón), Zaragoza, Spain
| |
Collapse
|
2
|
Bayona C, Alza L, Ranđelović T, Sallán MC, Visa A, Cantí C, Ochoa I, Oliván S, Herreros J. Tetralol derivative NNC-55-0396 targets hypoxic cells in the glioblastoma microenvironment: an organ-on-chip approach. Cell Death Dis 2024; 15:127. [PMID: 38341408 PMCID: PMC10858941 DOI: 10.1038/s41419-024-06492-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2023] [Revised: 01/19/2024] [Accepted: 01/23/2024] [Indexed: 02/12/2024]
Abstract
Glioblastoma (GBM) is a highly malignant brain tumour characterised by limited treatment options and poor prognosis. The tumour microenvironment, particularly the central hypoxic region of the tumour, is known to play a pivotal role in GBM progression. Cells within this region adapt to hypoxia by stabilising transcription factor HIF1-α, which promotes cell proliferation, dedifferentiation and chemoresistance. In this study we sought to examine the effects of NNC-55-0396, a tetralol compound which overactivates the unfolded protein response inducing apoptosis, using the organ-on-chip technology. We identified an increased sensitivity of the hypoxic core of the chip to NNC, which correlates with decreasing levels of HIF1-α in vitro. Moreover, NNC blocks the macroautophagic process that is unleashed by hypoxia as revealed by increased levels of autophagosomal constituent LC3-II and autophagy chaperone p62/SQSTM1. The specific effects of NNC in the hypoxic microenvironment unveil additional anti-cancer abilities of this compound and further support investigations on its use in combined therapies against GBM.
Collapse
Affiliation(s)
- Clara Bayona
- Tissue Microenvironment (TME) Lab, Institute for Health Research Aragón (IIS Aragón), Aragón Institute of Engineering Research (I3A), University of Zaragoza, 50018, Zaragoza, Spain
| | - Lía Alza
- Calcium Cell Signaling, IRBLleida, University of Lleida, Rovira Roure 80, 25198, Lleida, Spain
| | - Teodora Ranđelović
- Tissue Microenvironment (TME) Lab, Institute for Health Research Aragón (IIS Aragón), Aragón Institute of Engineering Research (I3A), University of Zaragoza, 50018, Zaragoza, Spain
- Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, 50018, Zaragoza, Spain
| | - Marta C Sallán
- Calcium Cell Signaling, IRBLleida, University of Lleida, Rovira Roure 80, 25198, Lleida, Spain
- Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, Charterhouse Square, London, EC1M 6BQ, UK
| | - Anna Visa
- Calcium Cell Signaling, IRBLleida, University of Lleida, Rovira Roure 80, 25198, Lleida, Spain
| | - Carles Cantí
- Calcium Cell Signaling, IRBLleida, University of Lleida, Rovira Roure 80, 25198, Lleida, Spain
| | - Ignacio Ochoa
- Tissue Microenvironment (TME) Lab, Institute for Health Research Aragón (IIS Aragón), Aragón Institute of Engineering Research (I3A), University of Zaragoza, 50018, Zaragoza, Spain
- Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, 50018, Zaragoza, Spain
| | - Sara Oliván
- Tissue Microenvironment (TME) Lab, Institute for Health Research Aragón (IIS Aragón), Aragón Institute of Engineering Research (I3A), University of Zaragoza, 50018, Zaragoza, Spain.
| | - Judit Herreros
- Calcium Cell Signaling, IRBLleida, University of Lleida, Rovira Roure 80, 25198, Lleida, Spain.
| |
Collapse
|
3
|
Bernabé-Caro R, García-Campelo R, Garrido P, Palmero R, Artal Á, Bayona C, Rodríguez-Abreu D, López-Brea M, Paredes A, Vicente D, Sánchez Torres J, Majem M, Diz P, Gordo R, Coca M, de Castro J. EP08.02-131 Alectinib after Crizotinib Failure in Patients with Advanced ALK-Positive NSCLC: Results from the Spanish Early Access Program. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.814] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
4
|
Llor C, Moragas A, Bayona C, Cots JM. Use of clinical vignettes to screen general practitioners who can participate in a clinical trial about stopping antibiotic treatment when this is no longer necessary. Rev Esp Quimioter 2021; 34:267-268. [PMID: 33784804 PMCID: PMC8179942 DOI: 10.37201/req/001.2021] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- C Llor
- Carles Llor, Health Centre Barcelona-2B (Via Roma), Spain.
| | | | | | | |
Collapse
|
5
|
Raghavan P, Tang A, Bilaloglu S, Bayona C, Stone J, Wilfred M, Hung C, Yousefi A, Caughey M. Dose-response relationship during motor learning with bimanual-to-unimanual training. Ann Phys Rehabil Med 2018. [DOI: 10.1016/j.rehab.2018.05.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
6
|
Margarit N, Bayona C, Navea S, Ferrero E, Malfeito J. Effects of water conductivity on microbubble size and distribution for seawater flotation in desalination pretreatment processes. Int J CMEM 2017. [DOI: 10.2495/cmem-v6-n2-251-259] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022] Open
|
7
|
Gámez-Pozo A, Anton-Aparicio L, Bayona C, Borrega P, Cornide M, Garcia R, de Portugal T, Ramos M, Perez-Carrion R, Espinosa E. 7160 POSTER MicroRNA Profiling in Peripheral Blood Predicts Major Response to Sunitinib in Metastatic Renal Cell Carcinoma. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)72075-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
8
|
Gámez-Pozo A, Antón Aparicio LM, Bayona C, Borrega P, Gallegos I, García Domínguez R, de Portugal T, Ramos M, Perez Carrion RM, Sánchez-Navarro I, Benguría A, Dopazo A, Madero R, Fresno-Vara JA, Bolos MV, Espinosa E. The role of microRNA profiling in peripheral blood in predicting early progression to sunitinib in renal cell carcinoma. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.e15039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Mesia R, Vázquez S, Grau JJ, García-Sáenz JA, Bayona C, Galceran JC, Irigoyen A, Lozano A, Mañós M, Cruz JJ. A single-arm phase II trial to evaluate the combination of cetuximab plus docetaxel, cisplatin, and 5-fluorouracil (TPF) as induction chemotherapy (IC) in patients (pts) with unresectable SCCHN. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.6015] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
6015 Background: TPF combination is the new standard IC. Adding cetuximab to PF chemotherapy is superior to PF alone in metastatic disease. We incorporated cetuximab into IC with TPF and subsequent radiotherapy (RT) in unresectable SCCHN. Methods: Phase II trial conducted in 7 Spanish hospitals. Previously untreated pts aged 18–70 yrs, ECOG PS 0–1 with unresectable SCCHN were eligible. Induction comprised T 75mg/m2 day 1, P 75mg/m2 day 1, F 750mg/m2 days 1–5, and cetuximab 250mg/m2 days 1, 8, and 15 (initial dose 400mg/m2 on cycle (C) 1, day 1), repeated every 21 days x 4 C, with prophylactic antibiotics and G-CSF support. Subsequently, pts received accelerated RT with a concomitant boost (69.9Gy) and cetuximab 250mg/m2 weekly. The primary endpoint was the objective response rate (RR) to cetuximab TPF as neoadjuvant therapy. Simon's optimal two-stage design was used to calculate the sample size of 49 evaluable pts. Results: 50 pts were enrolled: median age 54 yrs (33–68); 44 male; all stage IV (T4=31, N2–3=40). Primary sites were: oropharynx, 23; hypopharynx, 16; oral cavity, 5; larynx, 4.41(82%) pts received all 4 cycles of cetuximab TPF; 47 pts received ≥2 C and were evaluable for response using RECIST. 3 pts received <2 C (2 deaths from intercurrent disease and febrile neutropenia, 1 secondary neoplasm diagnosed). The table shows RR. Serious grade 3/4 adverse events (AEs) were: neutropenia 24%; neutropenic fever 20%; infection 6%; thrombocytopenia 4%; diarrhea 12%; hepatotoxicity 4%; hypomagnesemia 2%. Grade 3 AEs were: nausea/vomiting 2%; mucositis 6%; renal failure 4%; asthenia 4%; rash 4%; hypotension 4%. There were 2 AE-related deaths (febrile neutropenia and hepatic insufficiency). Conclusions: The addition of cetuximab to TPF IC in pts with unresectable SCCHN yields a high RR, mainly CR, potentially prolonging survival. Cetuximab TPF combination should be given to pts with good PS with specialized support provided. [Table: see text] [Table: see text]
Collapse
Affiliation(s)
- R. Mesia
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | - S. Vázquez
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | - J. J. Grau
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | - J. A. García-Sáenz
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | - C. Bayona
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | - J. C. Galceran
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | - A. Irigoyen
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | - A. Lozano
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | - M. Mañós
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | - J. J. Cruz
- Institut Catala d'Oncologia, Barcelona, Spain; Hospital Clínic de Barcelona, Barcelona, Spain; Hospital Clínico San Carlos, Madrid, Spain; Hospital General Yagüe, Burgos, Spain; Hospital del Mar, Barcelona, Spain; Hospital Virgen de las Nieves, Granada, Spain; Hospital Clínico de Salamanca, Salamanca, Spain
| | | |
Collapse
|
10
|
Llor C, Sierra N, Hernández S, Bayona C, Hernández M, Moragas A, Calviño O. [Compliance rate of antibiotic therapy in patients with acute pharyngitis is very low, mainly when thrice-daily antibiotics are given]. Rev Esp Quimioter 2009; 22:20-24. [PMID: 19308742] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/27/2023]
Abstract
OBJECTIVE To assess drug-compliance observed among patients with suspected streptococcal pharyngitis treated with twice-daily antibiotic regimens (b.i.d.) and others with thrice-daily regimens (t.i.d.). METHODS A prospective study in the primary care setting was designed in which patients with pharyngitis and three or more Centor criteria, non-allergic to beta-lactam agents, treated with several b.i.d and t.i.d antibiotic regimens based on doctor's choice, were recruited. Patient compliance was assessed with electronic monitoring. RESULTS A total of 113 patients were enrolled (64 in the t.i.d. group and 49 in the b.i.d. group). Mean openings ranged from 70.3 to 83.3% of the total amount of pills. All the parameters analysed indicated significantly worse compliance with the t.i.d. regimens. Eleven patients allocated to the t.i.d. group took at least 80% of the pills (17.2%), this being significantly lower than those who received b.i.d. antibiotics (59.2%; p < 0.001). The percentage of patients who opened the Medication Event Monitoring System (MEMS) container the satisfactory number of times a day was systematically lower among t.i.d. regimens, this being statistically significant from day three (p < 0.05). Patients assigned to t.i.d. regimens more frequently forgot the afternoon dose. CONCLUSION Compliance rate was very low, mainly when patients are given t.i.d antibiotic regimens. This may lead to storage of antibiotics and subsequent self-medication. New strategies addressed to improve drug-compliance with antibiotics among outpatients are therefore necessary.
Collapse
Affiliation(s)
- C Llor
- Centro de Salud Jaume I, Tarragona.
| | | | | | | | | | | | | |
Collapse
|
11
|
Bayona C, Lassaletta A, Pérez A, Sevilla J, Albi G, Villa JR, Madero L. Hemoptisis fatal secundaria a aspergilosis pulmonar invasiva en una paciente con leucemia mieloblástica aguda. An Pediatr (Barc) 2007; 67:278-9. [PMID: 17785168 DOI: 10.1016/s1695-4033(07)70621-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
12
|
Llor C, Cots JM, Molist N, Boada A, Bayona C, Bjerrum L. Reducción en la prescripción de antibióticos en la sinusitis mediante la realización de una auditoría. Aten Primaria 2006; 38:304-5. [PMID: 17020717 PMCID: PMC8210769 DOI: 10.1157/13092992] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
|
13
|
Porras JA, Bayona C, Gutiérrez MC, Vidal F. [Vertebral osteomyelitis due to Klebsiella pneumoniae]. An Med Interna 1994; 11:154-155. [PMID: 8011884] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
|